# US 2026/0085082 A1 · Kdm1a inhibitors for the treatment of disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085082 A1
- Document ID: US20260085082A1
- Status: Published application
- Kind: A1
- Application number: 19/137,840
- Filed: 2023-12-15
- Published: 2026-03-26
- Earliest claimed: 2022-12-23
- Assignees: Imago Biosciences, Inc.
- Applicants: Imago Biosciences, Inc.
- Inventors: Hugh Y. Rienhoff, Jr.; Cassandra Celatka; Amy E. Tapper; Nivedita Namdev; Michael Clare
- Web page: https://patentgrep.com/patent/US20260085082A1

## CPC

- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- C07F 9/65583: {each of the hetero rings containing nitrogen as ring hetero atom}
- A61K 31/415: 1,2-Diazoles
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07D 231/14: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 231/40: Acylated on said nitrogen atom
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 491/056: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

## Claims

### Claim 1

A compound of Formula I:
or a salt or tautomer thereof, wherein:
L1 is chosen from a bond and —(CH2)k—;
L2 is chosen from —C(O)NH—, —NHC(O)—, and —C(O)—;
R1 is chosen from phenyl, 5-membered monocyclic heteroaryl, and 10-membered bicyclic heteroaryl, either of which is substituted with one R5a and one or more R5b;
R2 is chosen from cyclohexyl, azetidinyl, pyrrolidinyl, and piperidinyl, any of which is optionally substituted with one or more R6;
k is chosen from 1, 2, and 3;
R4 is phenyl substituted with one R7a and one or more R7b;
R5a is chosen from CH3, CH2CH3, OCH3, 5- to 6-membered heterocycloalkyl, and 5-membered monocyclic heteroaryl, and 10-membered bicyclic heteroaryl, wherein the heterocycloalkyl and heteroaryl are optionally substituted by one or more R9;
each R5b is independently chosen from H, halo, and OCH3;
each R6 is independently chosen from —NHR8, —NHC(NH)NHR8, and —CH2NHR8;
R7a is cyano;
each R7b is independently chosen from halo;
each R8 is independently chosen from H and C1-3 alkyl; and
R9 is chosen from cyano, C1-3 alkyl, C1-3 alkoxy, hydroxy, phosphonate, oxo, or any combination thereof,
wherein if R5a is
or optionally substituted by one or more R9, each R5b is H.

### Claim 2 (depends on 1)

The compound of claim 1, or a salt or tautomer thereof, wherein the compound of Formula I is a compound of Formula III:

### Claim 3 (depends on 1)

The compound of claim 1, or a salt or tautomer thereof, wherein the compound of Formula I is a compound of Formula IV:

### Claim 4 (depends on 1)

The compound of claim 1, or a salt or tautomer thereof, wherein L1 is —(CH2)k—.

### Claim 5 (depends on 4)

The compound of claim 4, or a salt or tautomer thereof, wherein k is 1 or 2.

### Claim at position 6

6-7. (canceled)

### Claim 8 (depends on 1)

The compound of claim 1, or a salt or tautomer thereof, wherein L1 is a bond.

### Claim 9 (depends on 8)

The compound of claim 8, or a salt or tautomer thereof, wherein the compound of Formula I is a compound of Formula V:

### Claim 10 (depends on 1)

The compound of claim 1, or a salt or tautomer thereof, wherein R1 is phenyl substituted with R5a.

### Claim 11 (depends on 10)

The compound of claim 10, or a salt or tautomer thereof, wherein R5a is CH3 or OCH3.

### Claim 12

(canceled)

### Claim 13 (depends on 10)

The compound of claim 10, or a salt or tautomer thereof, wherein R1 is p-tolyl, 3-fluoro-4-methoxyphenyl, or 4-methoxyphenyl.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The compound of claim 1, or a salt or tautomer thereof, wherein R1 is monocyclic heteroaryl substituted with R5a.

### Claim 16 (depends on 15)

The compound of claim 15, or a salt or tautomer thereof, wherein R1 is isoxazol-5-yl substituted with R5a.

### Claim 17 (depends on 15)

The compound of claim 15, or a salt or tautomer thereof, wherein R5a is CH3 or CH2CH3.

### Claim 18 (depends on 17)

The compound of claim 17, or a salt or tautomer thereof, wherein R1 is 3-methylisoxazol-5-yl or 3-ethylisoxazol-5-yl.

### Claim 19 (depends on 10)

The compound of claim 10, or a salt or tautomer thereof, wherein R5a is chosen from pyrrolidin-1-yl, piperidin-1-yl, 4-oxopiperidin-1-yl, piperazin-1-yl, 3-oxopiperazin-1-yl, 1H-indazol-5-yl, 2H-indazol-5-yl, 1H-pyrazol-4-yl, and 1,1-dioxidothiomorpholin-4-yl, any of which is optionally substituted by one, two or three R9.

### Claim 20 (depends on 19)

The compound of claim 19, or a salt or tautomer thereof, wherein R5a is piperazin-1-yl which is optionally substituted by one R9.

### Claim 21 (depends on 20)

The compound of claim 20, or a salt or tautomer thereof, wherein R9 is C1-3 alkyl.

### Claim 22 (depends on 21)

The compound of claim 21, or a salt or tautomer thereof, wherein R9 is CH3.

### Claim 23 (depends on 20)

The compound of claim 20, or a salt or tautomer thereof, wherein R5a is 4-methylpiperazin-1-yl.

### Claim 24 (depends on 19)

The compound of claim 19, or a salt or tautomer thereof, wherein R5a is piperidin-1-yl optionally substituted by one or two R9.

### Claim 25 (depends on 24)

The compound of claim 24, or a salt or tautomer thereof, wherein R9 is chosen from methoxy, cyano, methyl, hydroxy, —OCH2CH2OH, —OCH2CH2CH2OH, and —OCH2CH2CH2OP(O)(OCH3)2.

### Claim 26 (depends on 1)

The compound of claim 1, or a salt or tautomer thereof, wherein L2 is —C(O)NH— or —NHC(O)—.

### Claim 27 (depends on 1)

The compound of claim 1, or a salt or tautomer thereof, wherein R2 is chosen from cyclohexyl, azetidinyl, pyrrolidin-3-yl, piperidin-3-yl, and piperidin-4-yl, any of which is optionally substituted with R6.

### Claim 28 (depends on 27)

The compound of claim 27, or a salt or tautomer thereof, wherein R2 is cyclohexyl optionally substituted with R6.

### Claim 29 (depends on 28)

The compound of claim 28, or a salt or tautomer thereof, wherein R6 is —NHR8.

### Claim 30 (depends on 29)

The compound of claim 29, or a salt or tautomer thereof, wherein R8 is H.

### Claim 31 (depends on 28)

The compound of claim 28, or a salt or tautomer thereof, wherein R2 is 3-aminocyclohexyl.

### Claim 32 (depends on 27)

The compound of claim 27, or a salt or tautomer thereof, wherein R2 is pyrrolidin-3-yl, optionally substituted with R6.

### Claim 33 (depends on 32)

The compound of claim 32, or a salt or tautomer thereof, wherein R6 is —NHR8.

### Claim 34 (depends on 33)

The compound of claim 33, or a salt or tautomer thereof, wherein R8 is H.

### Claim 35 (depends on 32)

The compound of claim 32, or a salt or tautomer thereof, wherein R2 is pyrrolidin-3-yl.

### Claim 36

The compound of or a salt or tautomer thereof, wherein L2 is —C(O)—.

### Claim 37 (depends on 1)

The compound of claim 1, or a salt or tautomer thereof, wherein R2 is chosen from azetidinyl and piperidin-1-yl, either of which is optionally substituted with R6

### Claim 38 (depends on 37)

The compound of claim 37, or a salt or tautomer thereof, wherein R2 is piperidin-1-yl optionally substituted with R6.

### Claim 39 (depends on 38)

The compound of claim 38, or a salt or tautomer thereof, wherein R6 is —NHR8.

### Claim 40 (depends on 39)

The compound of claim 39, or a salt or tautomer thereof, wherein R8 is H.

### Claim 41 (depends on 38)

The compound of claim 38, or a salt or tautomer thereof, wherein R2 is 3-aminopiperidin-1-yl.

### Claim 42 (depends on 37)

The compound of claim 37, or a salt or tautomer thereof, wherein R2 is azetidin-1-yl optionally substituted with R6.

### Claim 43 (depends on 42)

The compound of claim 42, or a salt or tautomer thereof, wherein R6 is chosen from —CH2NHR8 and —NHR8.

### Claim 44 (depends on 43)

The compound of claim 43, or a salt or tautomer thereof, wherein R8 is H.

### Claim 45 (depends on 1)

The compound of claim 1, or a salt or tautomer thereof, wherein R4 is phenyl substituted with one R7a and substituted with one R7b.

### Claim 46 (depends on 45)

The compound of claim 45, or a salt or tautomer thereof, wherein R4 is 3-fluoro-4-cyanophenyl or 4-cyanophenyl.

### Claim 47 (depends on 51)

The compound of claim 51, or a salt or tautomer thereof, wherein R4 is 3-fluoro-4-cyanophenyl.

### Claim 48 (depends on 1)

The compound of claim 1, or a salt or tautomer thereof, wherein the compound of Formula I is chosen from:

### Claim 49

A compound of Formula I or II:
or a salt or tautomer thereof, wherein:
L1 is a bond;
L2 is chosen from —C(O)NH—, —NHC(O)—, and —C(O)—;
R1 is phenyl substituted with R5a;
R2 is chosen from cyclohexyl, azetidinyl, pyrrolidinyl, and piperidinyl, any of which is optionally substituted with one or more R6;
R4 is phenyl which is substituted with one R7a and optionally substituted with one or more R7b;
R5a is OCH3;
each R6 is independently chosen from —NHR8, —NHC(NH)NHR8, and —CH2NHR8;
R7a is cyano;
each R7b is independently chosen from halo; and
each R8 is independently chosen from H and C1-3 alkyl.

### Claim 50 (depends on 49)

The compound of claim 49, or a salt or tautomer thereof, wherein L2 is —C(O)—.

### Claim 51 (depends on 49)

The compound of claim 49, or a salt or tautomer thereof, wherein L2 is —C(O)NH— or —NHC(O)—.

### Claim 52 (depends on 49)

The compound of claim 49, or a salt or tautomer thereof, wherein R1 is 4-methoxyphenyl.

### Claim 53 (depends on 49)

The compound of claim 49, or a salt or tautomer thereof, wherein R2 is chosen from piperidin-1-yl and piperidin-3-yl, either of which is optionally substituted with one or more R6.

### Claim 54 (depends on 53)

The compound of claim 53, or a salt or tautomer thereof, wherein R2 is piperidin-1-yl, optionally substituted with R6.

### Claim 55 (depends on 54)

The compound of claim 54, or a salt or tautomer thereof, wherein R6 is —NHR8.

### Claim 56 (depends on 55)

The compound of claim 55, or a salt or tautomer thereof, wherein R8 is H.

### Claim 57 (depends on 53)

The compound of claim 53, or a salt or tautomer thereof, wherein R2 is 3-aminopiperidin-1-yl.

### Claim 58 (depends on 53)

The compound of claim 53, or a salt or tautomer thereof, wherein R2 is piperidin-3-yl, optionally substituted with one or more R6.

### Claim 59 (depends on 58)

The compound of claim 58, or a salt or tautomer thereof, wherein R6 is chosen from —NHR8 and —CH2NHR8.

### Claim 60 (depends on 59)

The compound of claim 59, or a salt or tautomer thereof, wherein R8 is H.

### Claim 61 (depends on 58)

The compound of claim 58, or a salt or tautomer thereof, wherein R2 is piperidin-3-yl.

### Claim 62 (depends on 1)

The compound of claim 1, or a salt or tautomer thereof, wherein R4 is phenyl substituted with one R7a.

### Claim 63 (depends on 62)

The compound of claim 62, or a salt or tautomer thereof, wherein R4 is 4-cyanophenyl.

### Claim 64 (depends on 49)

The compound of claim 49, or a salt or tautomer thereof, wherein the compound of Formula I is chosen from:

### Claim 65

A pharmaceutical composition comprising a compound as recited in ai, or a salt or tautomer thereof, together with a pharmaceutically acceptable carrier.

### Claim 66 (depends on 65)

The pharmaceutical composition as recited in claim 65, formulated for oral administration.

### Claim 67 (depends on 65)

The pharmaceutical composition as recited in claim 65, additionally comprising another therapeutic agent.

### Claim 68 (depends on 1)

A method of inhibition of KDM1A comprising contacting KDM1A with a compound as recited in claim 1, or a salt or tautomer thereof.

### Claim 69 (depends on 1)

A method of treatment of a KDM1A-mediated disease comprising the administration of a therapeutically effective amount of a compound as recited in claim 1, to a patient in need thereof.

### Claim at position 69

70-75. (canceled)

### Claim 76 (depends on 1)

A method of treatment of a bone marrow failure syndrome comprising the administration of a therapeutically effective amount of a compound as recited in claim 1, or a salt or tautomer thereof.

### Claim at position 71

77-78. (canceled)

### Claim 79 (depends on 1)

A method of treatment of a disease resulting from mutations in globin genes which affect expression or function of the globin protein, comprising the administration of a therapeutically effective amount of a compound as recited in claim 1, or a salt or tautomer thereof, to a patient in need thereof.

### Claim 80 (depends on 1)

A method for achieving an effect in a patient, comprising the administration of a therapeutically effective amount of a compound as recited in claim 1, or a salt or tautomer thereof, to a patient, wherein the effect is chosen from an elevation of red blood cell count, an elevation of the red blood cell count of red cells containing fetal hemoglobin, an elevation in the total concentration of fetal hemoglobin in red cells, an elevation in the total concentration of fetal hemoglobin in reticulocytes, an increase in the transcription of the gamma globin gene in bone marrow-derived red cell precursors, a reduction in the number of sickle cell crises a patient experiences over a unit period of time, a halt to or prevention of tissue damage caused by sickling cells, a reduction in the proportion of red cells that undergo sickling under physiological conditions of relative hypoxia as measured using patient blood in an in vitro assay, an increase in the amount of histone 3 lysine methylation at lysine position 4, and/or a decrease in the amount of histone 3 methylation at lysine position 9 near or at the gamma globin promoter as assayed by ChIP using cells derived from a treated patient.

### Claim 81 (depends on 1)

A method of treatment of a hemoglobinopathy, comprising the administration of a therapeutically effective amount of a compound as recited in claim 1, or a salt or tautomer thereof, to a patient in need thereof.

### Claim at position 75

82-85. (canceled)

### Claim 86 (depends on 1)

A method of inhibiting at least one KDM1A function comprising the step of contacting KDM1A with a compound as recited in claim 1, or a salt or tautomer thereof, wherein the inhibition is measured by phenotype of red cells or their precursors either cultured or in vivo in humans or mouse or transgenic mice containing the human beta globin locus or portions thereof, the ability of cancer cells to proliferate, become differentiated, or induced to undergo apoptosis, the expression of specific genes known to be regulated by KDM1A activity, a change in the histone methylation states, a change in the methylation state of proteins known to be demethylated by KDM1A, expression of KDM1A-regulated genes, or binding of KDM1A with a natural binding partner.
